A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
about
Pancreatic Cancer from Molecular Pathways to Treatment OpinionPancreatic cancer from bench to bedside: molecular pathways and treatment optionsMolecular therapeutics in pancreas cancerCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansState of the art biological therapies in pancreatic cancerGenomic alterations in pancreatic cancer and their relevance to therapyNovel agents for advanced pancreatic cancerPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesMolecular landscape of pancreatic cancer: implications for current clinical trialsCIViC databaseKRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic AdenocarcinomaPersonalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Pancreatic cancer: Are "liquid biopsies" ready for prime-time?FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerPancreatic Cancer, A Mis-interpreter of the Epigenetic LanguageAdjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis.Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression.Current and future systemic treatment options in metastatic pancreatic cancer.Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.New targeted therapies in pancreatic cancer.Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerTrametinib modulates cancer multidrug resistance by targeting ABCB1 transporterMEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy.Interaction of tRNA with MEK2 in pancreatic cancer cellsTherapeutic Approaches to RAS Mutation.Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinomaMolecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision MedicineImpact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.Targeting RAS-mutant cancers: is ERK the key?Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.Trametinib in the treatment of melanoma.Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-AnalysisRisk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
P2860
Q26743482-280737EA-2D60-4323-9315-BD1CE90CA041Q26747524-DACC61E9-C085-46E6-97DF-734ACE41A871Q26751709-DA9E83B8-2DF8-4CC7-98F7-368761EC0993Q26767041-E5098C27-7813-4441-A963-491E9ACE9F1BQ26769941-DEC89653-D18A-4EA9-86E5-B7A48EF2F713Q26781443-33290B13-4773-45D4-8A13-A12D563F5C84Q26787087-7D05D24B-DC73-4B37-9F07-4BFFF2BB35F0Q26799714-DC75567F-CE7D-4BA8-B9A4-D569FC0739B3Q26824528-49525FDE-540F-445F-9D05-29CA4D487F33Q27612411-804B1315-CD49-4130-952B-52D40DDA6D7EQ27853365-615E7267-896F-4B5A-98D6-14C4D145E7EAQ28066268-CF47F34E-40EB-4C84-BD97-5529A227B0CCQ28068665-A38CDE71-FC32-4F46-8228-1BE6D45B0D66Q28075540-26FF6238-A1CC-4714-A159-54664737CC78Q28079735-A8F3707F-443A-4BA4-B045-B0F4FD111135Q30277400-393610FE-5FE8-47EA-A616-1D2E8B8EE1A9Q30313606-3294EFFB-C868-4DF0-A85D-45136487FB78Q33829355-E6586172-1D7C-493B-9F51-C0342B285B7AQ33948033-DAE6136D-7995-4603-8413-259381F9E4FBQ34127857-0EA56D40-7912-4A90-AE6E-24BAE00CA044Q34227791-E38395C2-5AF4-4CE1-A15C-63436AB2B8B6Q35604577-CCAAE184-BCFB-49D9-914B-E3444D9C6BA3Q35651453-92DC893E-1749-4AB8-8FDD-0AF3655B929AQ35657842-B1CE0742-B1C6-449A-B62B-6CE34324870EQ36021057-0C60430C-E5D7-46E3-880D-F36ABB8B0035Q36328021-37DFC95B-5224-4E23-9639-9E85B4B2C1B5Q36398735-90BE1EA4-13F6-4B13-9627-94CA0D32BB5FQ36666663-3C413B85-A8F2-472A-8840-033119C5B9DBQ37006130-1EC72595-D6F8-4B78-A576-D9087B5667AFQ37122874-36A3EA39-BD25-4EEA-BF65-6051CB5181DAQ37123636-275FE6D8-3363-494C-A6B2-6EF34C1C04EBQ37176648-380C26C3-6475-459C-982A-943D94037278Q37230991-B50753D7-CF66-4994-83E4-4FAC365B687CQ37609448-463A83FA-427B-4F68-AF7E-87D045A4148BQ38267209-7DDFF260-AA8F-4F34-89B0-A7670EC08B22Q38383457-4F6A23FE-DB71-422A-9E8A-46D2AD1E7C24Q38392273-4062068E-EF30-452D-A151-8AF0A25562BEQ38586046-BD1C4EC4-A505-439D-A288-848BD246C131Q38626515-5606E28A-BCC1-4699-A716-6C7DFC330531Q38631710-BC30D509-5665-42CA-BE5A-AB4C529EAB46
P2860
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@ast
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@en
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@nl
type
label
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@ast
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@en
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@nl
prefLabel
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@ast
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@en
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@nl
P2093
P921
P3181
P1476
A randomised, double-blind, pl ...... denocarcinoma of the pancreas.
@en
P2093
Bradley G Somer
Chung-Pin Li
Do-Youn Oh
Jeffrey R Infante
Joon Oh Park
Klaudia Steplewski
Max E Scheulen
Ngocdiep Le
Saifuddin M Kasubhai
Suman Redhu
P304
P3181
P356
10.1016/J.EJCA.2014.04.024
P577
2014-08-01T00:00:00Z